Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says

27 Oct 2003

• By The Pink Sheet

AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call

Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says

More from Archive

More from Pink Sheet